Amplicon-based next-generation sequencing (NGS) assays employ highly sensitive, rapid, and cost-effective methods to detect clinically actionable mutations for the diagnosis, prognosis, and treatment of patients with cancer. However, recognition of certain limitations inherent to amplicon-based NGS assays is crucial for the correct interpretation and reporting of variants in the clinical setting. In this report, we illustrate three different potential pitfalls related to amplicon-based NGS assays based on our institutional experience and highlight how the risk of such events can be minimised.
- medical oncology
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Handling editor Runjan Chetty.
JKT and KAD contributed equally.
Contributors JKT, KAD and CJS participated in the design and analysis of data for this manuscript. All authors participated in the writing of this manuscript.
Funding This study was funded by: NCI 2PO 1CA49605 (JZ) and the Stanford University School of Medicine, department of Pathology.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.